Author of 1 Presentation
SS 10.2 - Hepatobiliary phase-abbreviated MRI for HCC detection: a five-year, single-center, experience
Abstract
Purpose
To describe the five-year, single-center, clinical experience of abbreviated MRI (AMRI) protocol for HCC surveillance.
Material and methods
The radiology reports for all AMRIs performed through May 2019, at a single referral center, were retrospectively reviewed. Each AMRI examination was scored as negative (no or only definitely benign observations), subthreshold (observations <10 mm) or positive (observations ≥ 10 mm, not definitely benign). Each patient was categorized as surveillance-negative, surveillance-subthreshold or surveillance-positive according to their highest AMRI score they had during the inclusion period. Blinded to those categories, each patient was classified as positive or negative for HCC using a composite reference standard that integrated all available clinical, imaging and pathology data.
Results
1160 AMRIs were performed in 561 patients. 185 (33%) patients were lost to follow-up. Of the remaining 376 patients, 295 (79%) were surveillance-negative, 23 (6%) surveillance-subthreshold, and 58 (15%) surveillance-positive. Based on the composite reference standard, 292/295 (99%) surveillance-negative and 20/23 (87%) surveillance-subthreshold patients were HCC-negative (true negatives); 29/58 (50%) of surveillance-positive patients were HCC-positive (true positives). Sensitivity, specificity, and accuracy of surveillance AMRI were 86%, 91% and 90%, respectively.
Conclusion
Hepatobiliary-phase AMRI surveillance is feasible clinically in patients in whom US surveillance is compromised. Our preliminary single-center experience suggests it provides higher sensitivity (86% vs 78%) and specificity (98% vs 89%) [4] with a lower loss to follow-up (33% vs 38%) [5] than historically reported US surveillance.
Video-on-demand
Author of 1 Presentation
SS 10.2 - Hepatobiliary phase-abbreviated MRI for HCC detection: a five-year, single-center, experience (ID 832)
Abstract
Purpose
To describe the five-year, single-center, clinical experience of abbreviated MRI (AMRI) protocol for HCC surveillance.
Material and methods
The radiology reports for all AMRIs performed through May 2019, at a single referral center, were retrospectively reviewed. Each AMRI examination was scored as negative (no or only definitely benign observations), subthreshold (observations <10 mm) or positive (observations ≥ 10 mm, not definitely benign). Each patient was categorized as surveillance-negative, surveillance-subthreshold or surveillance-positive according to their highest AMRI score they had during the inclusion period. Blinded to those categories, each patient was classified as positive or negative for HCC using a composite reference standard that integrated all available clinical, imaging and pathology data.
Results
1160 AMRIs were performed in 561 patients. 185 (33%) patients were lost to follow-up. Of the remaining 376 patients, 295 (79%) were surveillance-negative, 23 (6%) surveillance-subthreshold, and 58 (15%) surveillance-positive. Based on the composite reference standard, 292/295 (99%) surveillance-negative and 20/23 (87%) surveillance-subthreshold patients were HCC-negative (true negatives); 29/58 (50%) of surveillance-positive patients were HCC-positive (true positives). Sensitivity, specificity, and accuracy of surveillance AMRI were 86%, 91% and 90%, respectively.
Conclusion
Hepatobiliary-phase AMRI surveillance is feasible clinically in patients in whom US surveillance is compromised. Our preliminary single-center experience suggests it provides higher sensitivity (86% vs 78%) and specificity (98% vs 89%) [4] with a lower loss to follow-up (33% vs 38%) [5] than historically reported US surveillance.